Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65  years-and-above in Switzerland

CONCLUSIONS: These results demonstrate that using PCV15 among adults aged 65 years-and-above can prevent a substantial number of PD cases and deaths while remaining cost-effective over a range of inputs and scenarios.PMID:38609806 | DOI:10.1016/j.vaccine.2024.04.016

Source: Vaccine - April 12, 2024 Category: Allergy & Immunology Authors: Kwame Owusu-Edusei Andrea Favre-Bulle Eleana Tsoumani Thomas Mutschler Nicole Cossrow Source Type: research